

Inventor(s): Lu et al.

Appln. No.: 09

733,956

Series Code ↑

Serial No. ↑

Group Art Unit

Examiner:

To Be Assigned

Atty. Dkt. P

0275378

70311

M#

Client Ref

Filed: December 12, 2000

Hon. Commissioner of Patents

Washington, D.C. 20231

Appln. Title:

Sir:

**REPLY/AMENDMENT/LETTER**

Date: July 12, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herewith by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

**FEE REQUIREMENTS FOR CLAIMS AS AMENDED**

1. Small Entity claim

A. ☒ NOT made

B. ☐ Withdrawn

C. ☐ made herewith

D. ☐ made previously

For B & C  
See **Required  
Separate Paper**  
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	14	**minus 14	0	x \$18/\$9 =	+ \$0 103/203
3. Independent Claims	4	***minus 4	0	x \$80/\$40 =	+ \$0 102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) ..... add				+ \$270/\$135 =	+ \$0 104/204
5. Original due Date: July 12, 2001		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$390/\$195 = (3 mos) \$890/\$445 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1390/\$695= (Usable only for 30 day/1mo.OA --- 5 mos) \$1890/\$945=	+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$0	
8. Extension Fee Attached				+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....				+ \$110/\$55	+ \$0 148/248
10. If IDS attached requires Official Fee under Rule 97 (c), ..... add				+ \$180	126
or if Rule 97(d) Request ..... add				+ \$180	126
11. After-Final Request Fee per rules 129(a) and 17(r) .....				+ \$710/355	+ \$0 146/246
12. No. of additional inventions for examination per Rule 129(b).....				x \$710/355 ea	+ \$0 149/249
13. Request for Continued Examination (RCE) .....				+ \$710/355	+ \$0 1179/1279
14. Petition fee for .....				+ \$0	
15. TOTAL FEE ENCLOSED =					\$0

15.

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 009901

0275378

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: DJB/AMX

Pillsbury Winthrop LLP  
Intellectual Property Group

By Atty: Donald J. Bird

Sig:

Reg. No. 25323

Fax: (703) 905-2500

Tel: (703) 905-2018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Group Art Unit: To Be Assigned

LU et al.

Examiner: To Be Assigned

Appln. No.: 09/733,956

Filed: December 12, 2000

FOR: TNFR-LIKE PROTEIN WITH DEATH DOMAIN

Date: July 12, 2001



**Submission Under 37 CFR §§ 1.821 Et Seq.,**

**and**

**Amendment to Comply With Sequence Listing Rules**

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the Notification to Comply with Requirements dated June 12, 2001, Applicants submit the following amendments to comply with Sequence Listing Rules.

**Amendments**

Please delete the Sequence Listing originally filed with the application that appears on pages 28-32 of the application. In its place, please enter the enclosed Sequence Listing on separate pages after the claims and abstract of the application.

On page 6 of the application enclosed herewith, please amend lines 3-17 to read as follows:

The present invention also provides purified nucleic acid sequences encoding DETH, variant thereof or fragment thereof. A preferred sequence encoding DETH is shown in SEQ ID NO:1. Nucleic acid sequence as used herein refers to an oligonucleotide, nucleotide or

A 1

polynucleotide and fragments or portions thereof and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. A nucleic acid sequence encoding DETH can be obtained from mammalian cells, preferably human cells using polymerase chain reaction techniques (PCR) and appropriate primers encompassing the 3' and 5' ends of the sequence encoding DETH shown in SEQ ID NO:1 with the nucleic acid in the cells serving as a template. A nucleic acid sequence encoding DETH was obtained from clone g1727750 obtained from the Merck/Washington University EST Project, St. Louis, Missouri, USA. Clone g1727750 was made from mRNA of a human colon epithelial cell line. Suitable primers for PCR include 5' primer - ttt aga tct atg aac tca aca gaa tcc aac tct tct gcc (SEQ ID No:3) and (SEQ ID No:4) 3' primer - gtc gac cta cag cag gtc agg aag atg gct ata aac ag . Suitable polymerase reaction conditions are those generally found in the art and exemplified herein in the examples.

A1

09/733,956

On page 23 of the application, please amend lines 23-28 to read as follows:

The novel protein DETH was identified after the assembly of expressed sequence tags (EST) sequences from a proprietary database base (Lifeseq data base, Incyte, Palo Alto, California) and the public Merck /Washington University EST sequence database. The initial identification of these ESTs was performed by basic local alignment search tool (BLAST) analysis of the databases using the death domain sequence of RIP (SEQ ID No:5) (TNF receptor interacting protein) :

A2

09/733,956

On page 24 of the application, please amend lines 17-18 to read as follows:

(SEQ ID NO: 3) Primer 1 - ttt aga tct atg aac tca aca gaa tcc aac tct tct gcc  
(SEQ ID NO:4) Primer 2 - gtc gac cta cag cag gtc agg aag atg gct ata aac ag

A3

On page 25 of the application, please amend lines 8-14 to read as follows:

For the extracellular region the following primers containing the restriction sites Bgl II/Sal I were used:

5' Bgl II for (SEQ ID NO:3) Primer 1 - ttt aga tct atg aac tca aca gaa tcc  
aac tct tct gcc

A4

3' EcoR I for (SEQ ID NO:6) Primer 3 - ttt gaa ttc caa atg ctc att gat gtc aa  
atg c

For the intracellular region the following primers containing Bgl II/ Eco  
RI restriction sites were used:

5' Bgl II for (SEQ ID NO:7) Primer 4 - ttt aga tct cgg aaa agc tcg agg act  
ctg aaa aag ggg

3' Sal I for (SEQ ID NO:4) Primer 2 - gtc gac cta cag cag gtc agg aag atg  
gct ata aac ag

AY  
G

09733956-060101